News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAYN.DE) Stock Rises as New Drugs Propel Revenue Increases



7/31/2013 8:05:12 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer AG (BAYN) stock rose to a record as stronger-than-predicted demand for new drugs outweighed a drop at plastics revenue that the German manufacturer said makes its full-year sales forecast “ambitious.” Revenue from products including the Xarelto blood thinner and Eylea eye medicine “are progressing considerably better than expected,” Leverkusen-based Bayer said in a statement today. The company raised its forecast for sales from new drugs to 1.4 billion euros ($1.9 billion euros) from a previous estimate of 1 billion euros.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES